62 results about "Bladder dysfunctions" patented technology

The present invention relates to compositions and methods for the administration of lipid-based vehicles to treat various disorders, including bladder inflammation, infection, dysfunction, and cancer. In various aspects, the compositions and methods of the invention are useful for prolonged delivery of drugs, e.g., antibiotics, pain treatments, and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system, and other organs or body systems. In particular, the present invention relates to liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin, and toxins, such as botulinum toxin, for the treatment of bladder conditions, including pain, inflammation, incontinence, and voiding dysfunction. Further related are methods of using these vehicles alone or in conjunction with antibodies, e.g., uroplakin antibodies, to improve duration of liposome attachment, and provide a long-term intravesical drug delivery platform. The present invention specifically relates to antibody-coated liposomes that are useful for targeting specific receptors for drug, peptide, polypeptide, or nucleic acid delivery. In one particular aspect, the present invention relates to liposomes coated with antibodies against nerve growth factor (NGF) receptor and containing NGF antisense nucleic acids, which are used as a treatment for neurogenic bladder dysfunction.

A medical system may include a control module and a therapy delivery module configured to generate and deliver electrical stimulation therapy to a patient. The control module may be configured to control the therapy delivery module to deliver electrical stimulation at a first stimulation intensity for a first time period, to deliver electrical stimulation at a second stimulation intensity for a second time period immediately following the first time period, and to deliver electrical stimulation at the first stimulation intensity for a third time period immediately following the second time period. The second stimulation intensity may be less than the first stimulation intensity. The electrical stimulation may elicit a first inhibitory physiological response during the first time period and a second inhibitory physiological response during the second time period. The second inhibitory physiological response may be greater than the first inhibitory physiological response.

The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:which relates to morphinan compounds useful as μ, δ, and / or κ receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.

A method is provided for treatment of bladder dysfunction of a patient. The method includes, at a site within a patient, measuring an indication of fill-level of a bladder of the patient, and in response to an indication of a high bladder fill-level, conveying a signal indicative of the high bladder fill-level to the patient in a humanly-perceptible manner. Other embodiments are also described.

Systems and Methods treat bladder dysfunctions using neuromodulation stimulation. Bladder emptying through stimulation of urethral afferents, and continence through stimulation of the dorsal genital nerve, is provided with one or more implanted pulse generators and one or more leads. A simple surgical procedure preserves all existing functions. A stimulating catheter is provided to be used as a clinical screening tool. The stimulating catheter is used to measure bladder pressures and stimulate the urethra at the same time.

Provided herein are methods for the treatment of bladder dysfunction, including detrusor hyperreflexia and detrusor external sphincter dyssynergia, fecal incontinence, and / or sexual dysfunction in an individual via the use of stably expressed light-responsive opsin proteins capable of selective hyperpolarization or depolarization of the neural cells that innervate the muscles responsible for physiologic functioning of urinary bladder, external urinary sphincter, external anal sphincter, and the male and female genitalia.

The present invention related to methods for treating neurological-urological conditions, including neurogenic bladder dysfunction. This is accomplished by administration of a botulinum toxin into the lower urinary tract of a patient with a neurogenic bladder dysfunction, including the bladder or urinary sphincter and the bladder wall.

Anchoring devices and methods for affixing an implanted lead of a neurostimulation system at a target location in a patient are provided herein. Such anchoring devices includes a helical body having a plurality of tines extending laterally outward from the lead when deployed that engage tissue to inhibit axial movement of the implanted lead. The plurality of tines are biased towards the laterally extended deployed configuration and fold inward towards the lead to a delivery configuration to facilitate delivery of the lead through a sheath. The tines may be angled in a proximal direction or in both proximal and distal directions and may include various features to assist in visualization and delivery of the lead. The anchor may be formed according to various methods, including laser cutting of a tubular section along with heat or reflow to set the material with the anchor in the deployed configuration and injection molding.

The present invention relates to compositions and methods for the administration of lipid-based vehicles to treat various disorders, including bladder inflammation, infection, dysfunction, and cancer. In various aspects, the compositions and methods of the invention are useful for prolonged delivery of drugs, e.g., antibiotics, pain treatments, and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system, and other organs or body systems. In particular, the present invention relates to liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin, and toxins, such as botulinum toxin, for the treatment of bladder conditions, including pain, inflammation, incontinence, and voiding dysfunction. Further related are methods of using these vehicles alone or in conjunction with antibodies, e.g., uroplakin antibodies, to improve duration of liposome attachment, and provide a long-term intravesical drug delivery platform. The present invention specifically relates to antibody-coated liposomes that are useful for targeting specific receptors for drug, peptide, polypeptide, or nucleic acid delivery. In one particular aspect, the present invention relates to liposomes coated with antibodies against nerve growth factor (NGF) receptor and containing NGF antisense nucleic acids, which are used as a treatment for neurogenic bladder dysfunction.

A method of diagnosing bladder pathology uses Vesico Internal Sphincter ElectroMyogram (VISEMG) waveforms obtained from a plurality of VISEMG electrodes disposed on a patient. The VISEMG waveforms are converted to noninvasive (NI) urodynamic graphs. Further, a programmed computer assesses the condition of the bladder based on the VISEMG waveforms. The method does not require traditional urodynamics or any other invasive procedure. An apparatus to perform the inventive method uses a plurality of VISEMG electrodes placed on the patient. Each electrode signal is amplified and filtered and converted to a digital signal. A computer converts the digital signals (the VISEMG waveforms) to NI urodynamic graphs. Any combination of the VISEMG waveforms, the NI urodynamic graphs, and the condition of the bladder based on the VISEMG waveforms can then be shown on a display screen.

A urological medical system for performing a controlled hydrodistention of the urinary bladder for treating a bladder dysfunction problem comprised of a programmed CPU with associated computer equipment for facilitating an automatic control of a treatment procedure to be performed on a patient, a saline solution warmer, a saline solution pump, a four-way catheter wherein a channel is provided for monitoring the pressure within the bladder during the procedure, a syringe for infusing a medicine through the catheter and a strapping device to secure the syringe and to slidingly engage the catheter to a leg of the patient. Desired parameters are monitored during the procedure and a desired pressure is maintained in the bladder for a predetermined time to perform the controlled hydrodistention of the urinary bladder.

The invention relates to a bladder power pump utilizing the magnetic force to assist the bladder to urinate, which comprises a magnetic active cell (1), a stator (2) and a magnetic controller (3), wherein, the magnetic controller (3) generates magnetic field if switched on and enables the magnetic force to work on the magnetic active cell (1); the magnetic active cell (1) comprises a flexible sheet (12) and a plurality of permanent magnetic sheets (13), and the permanent magnetic sheets (13) are enwrapped with the flexible sheet (12); the flexible sheet (12) enwrapping the permanent magnetic sheets (13) surrounds a gourd-shaped structure with the stator (2) to circle the outside of the bladder (10) to build a variable working cavity (11); the upper end of the flexible sheet (12) enwrapping the permanent magnetic sheets (13) is contacted and adhered with the stator (2); a through hole (9) of ureter communicating a ureter (8) with a ureter port (a) inside the bladder wall, and a urethra bayonet (7) held at a urethral meatus (b) of a urethra (8) are respectively arranged at the lower end of the flexible sheet (12) where the permanent magnetic sheets (13) are not enwrapped; and the lower end of the flexible sheet (12) where the permanent magnetic sheets (13) are not enwrapped is contacted and adhered with the stator (2). The invention can effectively assist the neurogenic bladder dysfunction sufferer to realize emiction and has the advantages of ingenious design, simple structure, safe use, convenience and practicality.

The present invention related to methods for treating neurological-urological conditions, including neurogenic bladder dysfunction. This is accomplished by administration of a botulinum toxin into the lower urinary tract of a patient with a neurogenic bladder dysfunction, including the bladder or urinary sphincter and the bladder wall.

Anchoring devices and methods for affixing an implanted lead of a neurostimulation system at a target location in a patient are provided herein. Such anchoring devices includes a helical body having a plurality of tines extending laterally outward from the lead when deployed that engage tissue to inhibit axial movement of the implanted lead. The plurality of tines are biased towards the laterally extended deployed configuration and fold inward towards the lead to a delivery configuration to facilitate delivery of the lead through a sheath. The tines may be angled in a proximal direction or in both proximal and distal directions and may include various features to assist in visualization and delivery of the lead. The anchor may be formed according to various methods, including laser cutting of a tubular section along with heat or reflow to set the material with the anchor in the deployed configuration and injection molding.

A urological medical system for performing a controlled hydrodistention of the urinary bladder for treating a bladder dysfunction problem comprised of a programmed CPU with associated computer equipment for facilitating an automatic control of a treatment procedure to be performed on a patient, a saline solution warmer, a saline solution pump, a four-way catheter wherein a channel is provided for monitoring the pressure within the bladder during the procedure, a syringe for infusing a medicine through the catheter and a strapping device to secure the syringe and to slidingly engage the catheter to a leg of the patient. Desired parameters are monitored during the procedure and a desired pressure is maintained in the bladder for a predetermined time to perform the controlled hydrodistention of the urinary bladder.

Methods, devices, and medicaments that include trospium are provided for use in the treatment of bladder dysfunction by locally administering the trospium into the bladder to achieve a sustained concentration of trospium in urine in the bladder sufficient to produce a therapeutic concentration of trospium in bladder tissue. The drug may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the drug into the urine in the bladder over an extended period of hours or days.

Provided herein are methods for the treatment of bladder dysfunction, including detrusor hyperreflexia and detrusor external sphincter dyssynergia, fecal incontinence, and / or sexual dysfunction in an individual via the use of stably expressed light-responsive opsin proteins capable of selective hyperpolarization or depolarization of the neural cells that innervate the muscles responsible for physiologic functioning of urinary bladder, external urinary sphincter, external anal sphincter, and the male and female genitalia.

The present invention is directed towards a method of regulating smooth muscle tone, comprising the introduction, into smooth muscle cells of a subject, of a DNA sequence encoding a protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth muscle cells of the subject to regulate smooth muscle tone in the subject. Specifically, the invention provides methods of gene therapy for treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders. The present invention also provides recombinant viral and non-viral vectors comprising DNA encoding a protein involved in the regulation of smooth muscle tone. Further provided by the present invention is a smooth muscle cell which expresses a gene encoding a protein involved in the regulation of smooth muscle tone.

There is provided according to the invention the use of Vitamin D compounds such as 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27-bishomo-20-epi-cholecalciferol in the prevention or treatment of bladder dysfunction.

Assays are provided for erectile and bladder dysfunction and vascular health (e.g., cardiovascular disease, hypertension), where the assays detect the expression of one or more of the human Vcsa1 gene family. The assays are also useful for monitoring the efficacy of treatment of these disorders.

Liposomes are used for intravesical drug delivery, especially delivery of botulinum toxin (BoNT) to help improve lower urinary tract symptoms by decreasing bladder irritation and frequency. The system uses a lower and safer dose of BoNT with lower risk of urinary retention. A simple instillation of liposome-BoNT as a liquid formulation into the bladder, in a typical volume of 30-60 ml, will achieve efficacy similar to that currently achieved with cystscopic needle injection of BoNT. The dose may be lower than that done by injection, thereby causing significantly less risk of urinary retention. Liposome-BoNT can protect the BoNT from bladder and urine breakdown. Liposome-BoNT instillation is more comfortable for the patients and allows many more doctors' offices to offer this form of treatment that would otherwise be restricted to doctors skilled and certified in cystoscopic BoNT injection.

The invention relates to a thermoplastic forming method of an implantable flexible magnetic control bladder pump. The thermoplastic forming method comprises the following steps of preparing a ferromagnetic complex from organic silica gel, polydimethylsiloxane resin and magnetic particles; preparing a hot-melt-state flexible non-magnetic substrate from organic silica gel, polydimethylsiloxane resin and a brightener; and carrying out injection molding, curing and forming on the hot-melt-state flexible non-magnetic matrix and the ferromagnetic complex, so that the implantable flexible magnetic control bladder pump is manufactured. The implantable flexible magnetic control bladder pump prepared through the thermoplastic forming method can effectively and permanently solve dysuria diseases such as nerve type bladder dysfunction and the like, and after the flexible magnetic control bladder pump is implanted through an operation, the normal urination function can be realized through high torque of magnetic field force applied by an external magnetic field under the condition of not connecting any additional pipeline.

The invention relates to a thermoplastic forming mold of an implantable flexible magnetic control bladder pump. The bladder pump comprises a mold core, a front mold box, a rear mold box, a front mold box insertion block group and a rear mold box insertion block, wherein the mold core is composed of a mold core main body and a mold core handle; the shape of the mold core main body is matched with the shape of a filled bladder; the shape of the mold core handle is matched with the shape of a urethra connected with the bladder; the top of the front mold box is provided with a plurality of insertion grooves matched with the front mold box insertion block group; a front mold containing cavity is formed in the front mold box; an insertion hole matched with the rear mold box insertion block is formed in the top of the rear mold box; a rear mold containing cavity is formed in the rear mold box; and the mold core handle is arranged in the rear mold containing cavity. The implantable flexible magnetic control bladder pump prepared by the thermoplastic forming mold can effectively and permanently solve dysuria diseases such as nerve type bladder dysfunction; and after the flexible magnetic control bladder pump is implanted through an operation, the normal urination function can be realized through high torque of magnetic force applied by an external magnetic field under the condition that no additional pipeline is connected.

Methods for treating a bladder dysfunction by injecting a clostridial derivative to a target site below the bladder midline are described.

Liposomes are used for intravesical drug delivery, especially delivery of botulinum toxin (BoNT) to help improve lower urinary tract symptoms by decreasing bladder irritation and frequency. The system uses a lower and safer dose of BoNT with lower risk of urinary retention. A simple instillation of liposome-BoNT as a liquid formulation into the bladder, in a typical volume of 30-60 ml, will achieve efficacy similar to that currently achieved with cystscopic needle injection of BoNT. The dose may be lower than that done by injection, thereby causing significantly less risk of urinary retention. Liposome-BoNT can protect the BoNT from bladder and urine breakdown. Liposome-BoNT instillation is more comfortable for the patients and allows many more doctors' offices to offer this form of treatment that would otherwise be restricted to doctors skilled and certified in cystoscopic BoNT injection.

The present invention relates to a neuromodulation apparatus and methods of using the neuromodulation apparatus for treating bladder dysfunction.

The present invention is directed towards a method of regulating smooth muscle tone, comprising the introduction, into smooth muscle cells of a subject, of a DNA sequence encoding a protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth muscle cells of the subject to regulate smooth muscle tone in the subject. Specifically, the invention provides methods of gene therapy for treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders. The present invention also provides recombinant viral and non-viral vectors comprising DNA encoding a protein involved in the regulation of smooth muscle tone. Further provided by the present invention is a smooth muscle cell which expresses a gene encoding a protein involved in the regulation of smooth muscle tone.

The invention provides methods of regulating smooth muscle tone in a subject, comprising the introduction, into smooth muscle cells of the subject, of a DNA sequence encoding a potassium channel protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth muscle cells of the subject to regulate smooth muscle tone in the subject. The invention provides methods of gene transfer for treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders.

The invention discloses a radix linderae extract for treating diabetic bladder dysfunction disease and a preparation method thereof. The radix linderae extract prepared by the preparation method has a perfect curative effect on bladder dysfunction disease and particularly diabetic bladder dysfunction disease and can be used for preparing a related medicine; and the medicine consists of the radix linderae extract and medically acceptable accessories, wherein 500-5,000mg of radix linderae extract is contained in daily dosage. The radix linderae extract and medicine thereof can regulate the diastolic and systolic tension of the bladder smooth muscle so as to regulate the bladder function; and the mechanism is related to a cholinergic nerve receptor (M receptor), a beta-adrenergic receptor (beta-AR) and a non-cholinergic non-adrenergic TRPV1 passage. Therefore, the radix linderae extract can be used for preventing and treating bladder dysfunction disease and has wide application prospects in preparing a medicine for preventing and / or treating diabetic bladder dysfunction disease.

The invention provides methods of regulating smooth muscle tone in a subject, comprising the introduction, into smooth muscle cells of the subject, of a DNA sequence encoding a potassium channel protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth muscle cells of the subject to regulate smooth muscle tone in the subject. The invention provides methods of gene transfer for treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders.